Karyopharm Therapeutics (KPTI) Reports Q4 Loss of $0.81/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10
March 15, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following the company's 4Q earnings report. Total operating expenses for 4Q were $29.3M consisting of $24.1M of R&D vs. a $24.5M estimate and... More
